Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material Patents (Class 424/130.1)
  • Patent number: 10994002
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 4, 2021
    Inventors: Charles Akle, John Grange, Kevin Bilyard
  • Patent number: 10995130
    Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: May 4, 2021
    Assignee: Biogen MA Inc.
    Inventors: Kevin Maloney, Ke Gong, Roy Alston
  • Patent number: 10987425
    Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 27, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hwa Peoung Rim, Hyun Uk Kim, Ho Taek Im, Sang Yun Kim, Hyung Kyu Lim, Sung Min Bae, Se Chang Kwon
  • Patent number: 10988533
    Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 27, 2021
    Assignees: UNM Rainforest Innovations
    Inventors: Bridget S. Wilson, Stuart S. Winter, Michael Frank Erasmus, Michael Horowitz
  • Patent number: 10987405
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 27, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10980885
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 20, 2021
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10980884
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: April 20, 2021
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10980748
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: April 20, 2021
    Assignee: VHsquared Ltd.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • Patent number: 10973918
    Abstract: The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: April 13, 2021
    Assignee: ANUBIS BIO CORPORATION
    Inventor: Thomas A. Schultz
  • Patent number: 10968278
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: April 6, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Preethi Aavali Sridhara Sundaram, Ronald Buggage, Karen W. Chu, Valérie Corp dit Genti, Kristine A. Erickson, Dominique Mery-Mignard, Rafael Varona, Robert L. Vitti
  • Patent number: 10961536
    Abstract: The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: March 30, 2021
    Assignee: INSTITUT PASTEUR
    Inventors: Lucie Peduto, Gerard Eberl
  • Patent number: 10961288
    Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: March 30, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Patent number: 10960068
    Abstract: Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO: 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: March 30, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Billy Hargis, Neil R. Pumford, Young Min Kwon, Sherryll Layton
  • Patent number: 10953093
    Abstract: The present invention relates to a method for the treatment of cancer in a subject which comprises the steps of: (i) administering electroporation to a tumour in the subject; and (II) administering a T or B-cell activiating agent to the subject, wherein step (i) and (II) may be performed in either order.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: March 23, 2021
    Assignee: University College Cork
    Inventors: Declan Soden, Patrick Forde, Morgan O'Brien
  • Patent number: 10954515
    Abstract: The present invention relates to products and compositions as well as their therapeutic uses in human or veterinary medicine. In particular, the invention provides ZNF555 as a new therapeutic target for the prevention or treatment of a musculoskeletal disease in a subject. Particular embodiments include wherein the musculoskeletal disease is selected from Facioscapulohumeral Dystrophy (FSHD), a myopathy, musculoskeletal fibromatosis and muscular cachexia.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: March 23, 2021
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Iryna Pirozhkova, Vasily Ogryzko
  • Patent number: 10946053
    Abstract: The present invention relates to a composition comprising the mixed extract of mulberry and Poria cocos peel for preventing, improving or treating neurodegenerative disorders. The mixed extract of mulberry and Poria cocos peel which is the active ingredients contained in the composition of the present invention, has a memory improving activity through inhibiting of acetylcholine esterase and a neuroprotective effects and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: March 16, 2021
    Assignee: NeuroBo Pharmaceuticals, Inc.
    Inventors: Sang Zin Choi, Mi Won Sohn, Hyo Sang Go, Ja Young Ryu, Jin Seok Jeong, Song Hyen Choi, Eun Jin Kim, Young Woong Cho, So Young Kim
  • Patent number: 10947298
    Abstract: Described herein dog and cat food additives and compositions comprising secretory IgA.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 16, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark E. Cook, Lisa Ann Krugner-Higby, James Mukasa Ntambi
  • Patent number: 10947543
    Abstract: The present invention provides a small hairpin nucleic acid molecule that is capable of stimulating interferon production. The nucleic acid molecule of the present invention has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5? triphosphate or a 5? diphosphate.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 16, 2021
    Assignee: Yale University
    Inventors: Anna Marie Pyle, Andrew Kohlway, Dahai Luo, David Rawling, Akiko Iwasaki
  • Patent number: 10946076
    Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: March 16, 2021
    Assignees: The Research Foundation for The State University of New York, Icahn School of Medicine at Mount Sinai
    Inventors: Ioannis Danias, Oscar A. Candia, Rosana Gerometta
  • Patent number: 10948488
    Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 16, 2021
    Assignee: Nautilus Biotechnology, Inc.
    Inventor: Parag Mallick
  • Patent number: 10941193
    Abstract: Anti-microbial monoclonal antibodies and variant antibodies having a heavy chain constant regions with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: March 9, 2021
    Inventor: Nicholas B. Lydon
  • Patent number: 10939862
    Abstract: A diagnostic system for measuring and analyzing startle response of a subject comprises a stimuli delivery module, whereby startle stimuli and prepulse stimuli are delivered to subject; said diagnostic system comprises at least one sensor module, whereby the startle response of subject are detected and recorded; said sensor module comprises at least one electrode and one eyeblink response measuring means; and said diagnostic system comprises a diagnosis module whereby the features of the startle response and prepulse inhibition of subject are extracted and analyzed.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 9, 2021
    Inventor: Yusuf Ozgur Cakmak
  • Patent number: 10941146
    Abstract: Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one compound of any one of Formula I-a to I-n, II, II-a, II-b or III or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 9, 2021
    Assignees: NOVITA PHARMACEUTICALS, INC., CORNELL UNIVERSITY
    Inventors: Xin-Yun Huang, Christy Young Shue
  • Patent number: 10933097
    Abstract: The method of treating a bacterial infection using colostrum includes administering an effective amount of colostrum to a subject in need thereof. The infection can be caused by G+ or G? bacteria. The colostrum administered may be selected from the group consisting of bovine colostrum, camel colostrum, and a mixture of bovine colostrum and camel colostrum. The bacterial infection may be selected from the group consisting of Staphylococcus aureus subs. aureus Rosenbach, Escherichia coli, Pseudomonas aeruginosa, and Methicillin-resistant Staphylococcus aureus. A colostrum composition can include a mixture of bone and camel colostrum and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: March 2, 2021
    Assignee: KING SAUD UNIVERSITY
    Inventors: Khawla Ibrahim Alsamhary, Nagwa Mohamed Mohamed Amin Aref, Adel Almogren
  • Patent number: 10933115
    Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 2, 2021
    Assignees: THE TRUSTEES OF DARTMOUTH COLLEGE, KING'S GOLLEGE LONDON
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle Lemercier, Elizabeth Nowak, Janet Lines, Li Wang, Mark Spaller
  • Patent number: 10925952
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 23, 2021
    Assignee: IMMODULON THERAPEUTICS LIMITED
    Inventors: Charles Akle, John Grange, Kevin Bilyard
  • Patent number: 10925960
    Abstract: A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.
    Type: Grant
    Filed: June 17, 2017
    Date of Patent: February 23, 2021
    Assignee: SRI INTERNATIONAL
    Inventors: Kathlynn C. Brown, Benjamin J. Umlauf
  • Patent number: 10919965
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 16, 2021
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITED
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • Patent number: 10918692
    Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: February 16, 2021
    Assignee: HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
    Inventors: Xiaofang Luo, Zuodong Qin, Fulin He, Xiaoping Ouyang, Zhizhang Li, Changjian Li, Qianrui Peng, Zhesheng Chen
  • Patent number: 10918717
    Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 16, 2021
    Assignee: GREEN CROSS CORPORATION
    Inventors: Yong Woon Choi, Yoo Hoon Kim, Jungsub Choi
  • Patent number: 10912813
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 9, 2021
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Patent number: 10905767
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 2, 2021
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Theodore Yun
  • Patent number: 10908153
    Abstract: The invention relates to a method of identifying molecules which inhibit the virulence machinery of Pseudomonas aeruginosa, to a device for identifying a molecule which inhibits the virulence machinery of Pseudomonas aeruginosa, to novel compounds which inhibit the virulence machinery of Pseudomonas aeruginosa, to compounds for use for preventing and/or treating a pathogenic infection caused by Pseudomonas aeruginosa and also to pharmaceutical compositions for preventing and/or treating a pathogenic infection caused by Pseudomonas aeruginosa.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: February 2, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    Inventors: Yung-Sing Wong, Sophie Ple, Ina Attree, Caroline Barette
  • Patent number: 10906972
    Abstract: The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: February 2, 2021
    Assignees: Tohoku University, ZENOAQ RESOURCE CO., LTD.
    Inventors: Yukinari Kato, Mika Kaneko, Satoshi Ogasawara
  • Patent number: 10906977
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 2, 2021
    Assignee: Maine Medical Center Research Institute
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • Patent number: 10899846
    Abstract: Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the second
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 26, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Tilman Schlothauer
  • Patent number: 10898541
    Abstract: Disclosed are antimicrobial peptides capable of inhibiting and killing multiple drug-resistant bacteria, including XH-12C, XH-12B and XH-12A. The application further provides uses of the antimicrobial peptides in the preparation of a drug for inhibiting and/or killing fungi, Gram-positive bacteria, Gram-negative bacteria and drug-resistant bacteria and in the manufacture of medical carriers.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: January 26, 2021
    Assignee: HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
    Inventors: Xiaofang Luo, Zuodong Qin, Fulin He, Xiaoping Ouyang, Zhizhang Li, Changjian Li, Qianrui Peng, Zhesheng Chen
  • Patent number: 10899833
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: January 26, 2021
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Patent number: 10899802
    Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 26, 2021
    Assignee: PFIZER INC.
    Inventors: Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Kathrin Ute Jansen, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
  • Patent number: 10894820
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 19, 2021
    Assignee: GENEURO SA
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • Patent number: 10894832
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 19, 2021
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 10894082
    Abstract: The present description relates to an anti-S1008 protein for treating leukemia. More specifically, is disclosed anti-S100A8 antibody that specifically binds to a portion of S100A8 protein and/or a S100A8/S100A9 heterodimer for treating leukemia.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: January 19, 2021
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Philippe Tessier, Malika Laouedj, Frédéric Barabe, Natalie Pagé
  • Patent number: 10888619
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 12, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10881732
    Abstract: The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 5, 2021
    Assignee: Maine Medical Center Research Institute
    Inventors: Peter C. Brooks, Jennifer M. Caron, Liangru Contois
  • Patent number: 10883990
    Abstract: There is provided methods of determining tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and (a) secrete TNF-? without secreting IFN-?; or (b) secrete IFN-? without secreting TNF-?; (iv) identifying those cells of (iii) which are also CCR7 and, CD127 negative; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of T-cells calculated in (v) correlates to TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: January 5, 2021
    Assignee: MJO INNOVATION LIMITED
    Inventors: Ajit Lalvani, Katrina Mary Pollock, Graham Taylor, Hilary Sian Whitworth
  • Patent number: 10883989
    Abstract: Provided are peptides suitable for early detection of active M. tuberculosis (Mtb) infection in immunocompromised individuals. The peptides can form complexes with antibodies directed to Mtb antigens MS, MPT51, ESAT6 or CFPIO. Also provided are methods for detected of complexes of the peptides and the antibodies. The presence of complexes aids in predicting risk in immunocompromised individuals of developing active tuberculosis.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 5, 2021
    Assignee: New York University
    Inventor: Suman Laal
  • Patent number: 10870704
    Abstract: An isolated or recombinant CD83 binding protein may include an antigen binding domain, wherein the antigen binding domain binds specifically to CD83 or a cell expressing CD83.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: December 22, 2020
    Assignee: KIRA BIOTECH PTY LIMITED
    Inventors: Joanne L. Casey, Andrew M. Coley
  • Patent number: 10866250
    Abstract: Methods and apparatuses for monitoring the state of health of dairy cows, in particular of entire dairy herds are provided. The method is based on analysing the haptoglobin (HP) biomarker and part of the polymeric immunoglobulin receptor (PIGR), the secretory component (SC), in a milk sample. This allows diagnosis of mastitis or systemic diseases which occur outside the udder on the basis of the protein biomarker described here. This further allows regular monitoring of the general state of health of a dairy herd. Diagnostic methods, apparatuses, and diagnostic kits for carrying out these methods are included.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: December 15, 2020
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V
    Inventors: Joerg Lehmann, Katharina Zoldan
  • Patent number: 10865243
    Abstract: In a first aspect, the present invention relates to a recombinant polypeptide containing a domain comprising at least two antibody units whereby the first antibody unit is an anti-CD30 single chain antibody unit while the second antibody unit is a antibody unit being specific for an antigen present on the surface of a predetermined target cell. In particular, the present invention relates to a recombinant polypeptide containing at least the following domains starting from the N-terminus to the C-terminus: a first domain containing an anti-CD30 single chain antibody unit, in particular, HRS3 scFv of SEQ ID No. 2 or homologs thereof having at least 70% identity with SEQ ID No. 2 binding specifically to CD30, and an antibody unit said antibody unit being specific for an antigen present on the surface of a predetermined target cell, in particular, being specific for a tumor-associated antigen; optionally a spacer domain; a trans-membrane domain; and a cytoplasmatic signalling domain.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: December 15, 2020
    Inventors: Hinrich Abken, Andreas Hombach
  • Patent number: 10858447
    Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignees: Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.
    Inventors: Hai Wu, Bo Chen, Hui Feng, Sheng Yao, Jian Yao, Hongchuan Liu, Libo Zhang, Jing Zhang, Dan Meng